COPD is a heterogenous and progressive disease, driven by distinct chronic immune processes.1 In a round table discussion, leading respiratory experts discussed 
<ol style="margin-top:8px; margin-bottom:11px">
 <li style="margin-top:8px; margin-bottom:11px; margin-left:8px">What are the current unmet needs for patients with COPD?</li>
 <li style="margin-top:8px; margin-bottom:11px; margin-left:8px">How do different inflammatory pathways in COPD impact disease pathobiology and progression?</li>
 <li style="margin-top:8px; margin-bottom:11px; margin-left:8px">Biomarkers to guide COPD management. </li>
</ol>
&nbsp;
The round table was chaired by Professor Paola Rogliani of the University of Rome, Italy. Other respiratory experts on the panel were:
<ul>
 <li style="margin-top: 8px; margin-bottom: 11px;">Dr MeiLan Han, Professor of Pulmonary Critical Care Medicine at the University of Michigan, Ann Arbor, MI, USA.</li>
 <li style="margin-top: 8px; margin-bottom: 11px;">Dr Marc Miravitlles, a chest physician from the Hospital Universitari Vall d’Hebron, Barcelona, Spain.</li>
</ul>
<h2 style="margin-top: 8px; margin-bottom: 11px;"><a>What are the current unmet needs for patients with COPD?</a></h2>
Watch the video below to gain insights on this topic from the respiratory experts

The article "Current Unmet Needs for Patients with COPD" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts explore various aspects, such as the role of inflammatory pathways in disease progression, the importance of biomarkers in COPD management, and the significant global burden of COPD. The discussion also highlights the challenges in diagnosing COPD early, the impact of exacerbations on lung function and quality of life, and the need for more personalized treatment approaches .

CHRONIC-OBSTRUCTIVE-PULMONARY-DISEASE-(COPD)

RESPIRATORY

A video series on round table discussions featuring experts: Current unmet needs for patients with COPD

In this video, Dr Miravitlles discusses the current unmet needs in patients with COPD, followed by a panel discussion with other experts.
<h2 style="margin-top: 8px; margin-bottom: 11px;"><a>How Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines chronic obstructive pulmonary disease (COPD)?</a></h2>
COPD is a heterogeneous lung condition characterized by chronic respiratory symptoms (dyspnea, cough, expectoration and/or exacerbations) due to abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.1
According to Dr Miravitlles, “Despite airflow obstruction in all patients with COPD, they may have very different types of disease.”
<h3 style="margin-top: 8px; margin-bottom: 11px;"><a>Global burden of COPD</a></h3>
COPD is a leading cause of morbidity and mortality.2 Global burden of COPD continues to increase.2 COPD is currently the third leading cause of death worldwide and the seventh leading cause of poor health and disability.3 
Smoking is the leading risk factor for the development of COPD.4,5 Dr Miravitlles highlighted, “Cigarette smoking is the leading cause of COPD in most developed countries — in the United States, in Europe, Japan and around the world.” However, 25%–45% of people with COPD in the United States and other developed countries reportedly have never smoked.4 In low- and middle-income countries, up to 70% of cases of COPD are non-smokers.6 
Second-hand smoke exposure has been implicated as a potential risk factor for the development of COPD in non-smokers.5 Non-smoking risk factors may include indoor4 and outdoor air pollution and infections.6
<h3 style="margin-top: 8px; margin-bottom: 11px;"><a>COPD exacerbations&nbsp;</a></h3>
<h4 style="margin-top: 8px; margin-bottom: 11px;"><a>Incidence and prevalence</a></h4>
Studies have shown that exacerbations are common among patients with COPD.7,8,9
Dr Miravitlles noted, “More than one-half of patients with moderate-to-severe COPD experience exacerbations.”

Of 52% of patients with moderate-to-severe exacerbations in the Spanish study, 12% had 1 severe exacerbation, 8% had ≥2 moderate and/or severe exacerbations, and 9% had ≥3 moderate-to-severe exacerbations.8
<h4>Clinical impact</h4>
Dr Miravitlles highlighted the clinical impact of COPD exacerbations, “Patients with frequent exacerbations also have an accelerated decline in lung function.”&nbsp; Moreover, exacerbations can have potentially irreversible effects on lung function. In a retrospective analysis of the 4-year, randomized, double-blind, placebo-controlled, parallel group UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, the annual decline in post-bronchodilator FEV1 was nearly doubled after a single moderate-to-severe exacerbation.10
For more information, please watch the video on <a href="https://pro.campus.sanofi/copd/articles/the-burden-and-risk-of-exacerbations-in-copd-according-to-dr-surya-bhatt">the burden and risk of exacerbations in COPD presented by Dr Surya Bhatt</a>, a distinguished professor of medicine at the University of Alabama at Birmingham and a COPD researcher
An observational study conducted using data from the UK clinical practice research datalink (<a href="https://www.cprd.com/">CPRD</a>) Aurum database, reported that the frequency of future exacerbations increased with increased frequency and severity of exacerbations at baseline in patients with COPD.
As emphasized by Dr Miravitlles, “Even a single moderate exacerbation increases risk of future exacerbation events,” the adjusted incidence rate ratio for future exacerbation (vs 0 exacerbation) was 1.70 (95% CI: 1.66–1.74) with 1 moderate exacerbation according to the CPRD Aurum database study.7
Read this article to find out more about the <a href="https://pro.campus.sanofi/copd/articles/the-impact-of-exacerbations-in-copd">the impact of exacerbations in COPD</a>
The CPRD Aurum database study also reported an association between increased frequency and severity of baseline exacerbations with mortality (all cause/COPD-related/cardiovascular-related).7
<h4>Impact on quality of life</h4>
While explaining impact of exacerbations, Dr Miravitlles further highlighted, “It’s not just lung function, patients with COPD complain of impairment in quality of life, which is even more impaired when they experience a severe exacerbation.” Exacerbations have an impact on daily activities of the patient, such as walking, sleeping, talking, and sexual life.11 Furthermore, reduced physical activity levels have been associated with an increased risk of further exacerbations and mortality.11
<div>
 <div>
 &nbsp;
 </div>
</div>

“There is a vicious circle of more symptoms, reduced activity, even more symptoms. We need to break this vicious circle by providing adequate treatment for not only acute exacerbations, but also for stable COPD”, Dr Miravitlles pointed out.
<h3 style="margin-top: 8px; margin-bottom: 11px;"><a>COPD exacerbations despite maximal inhaled therapy</a></h3>
<ol start="8" style="margin-top:8px; list-style-type:lower-alpha">
 <li class="Default" style="margin-top:8px" value="4828">Miravitlles called attention to frequent exacerbations despite triple therapy with inhaled corticosteroids (ICS), long-acting muscarinic antagonist (LAMA) and long-acting β2 agonist (LABA), representing a crucial unmet need,12 “There are patients who despite optimal or maximal inhaled therapy are still experiencing exacerbations.”</li>
</ol>
Discover more about <a href="https://pro.campus.sanofi/copd/articles/understanding-and-managing-copd-exacerbations" style="color:#0563c1; text-decoration:underline">understanding and managing COPD exacerbations</a>
In this context, Dr Miravitlles discussed a UK study involving 43,753 patients with COPD receiving maintenance therapy. Of the overall study population, 6480 (15%) patients were frequent exacerbators, defined as those who had experienced ≥1 severe or ≥2 moderate exacerbations despite ≥3 months of continuous treatment with triple therapy in the prior 12 months.12 During the 12-month follow-up in the UK study, frequent exacerbators reported a mean of 2.55 (vs 1.19) exacerbations even after triple therapy. These patients also had a significantly higher risk of COPD-related death (5.8% vs 2.1%, P &lt;0.0001) than other maintenance therapy-treated patients. Importantly, almost one-quarter of frequent exacerbators exhibited a high blood eosinophil count (≥250 cells/µL) and ≥3 exacerbations.12
Learn more about <a href="https://pro.campus.sanofi/copd/articles/blood-eosinophils-as-a-biomarker-in-patients-with-copd" style="color:#0563c1; text-decoration:underline">blood eosinophils as a biomarker in patients with COPD</a>
<h3 class="Default" style="margin-top: 8px;"><a>Unmet needs in COPD&nbsp;</a></h3>
In his concluding slide, Dr Miravitlles presented the conclusions and recommendations reached by the Lancet Commission from their analysis of the current landscape of COPD.2 
COPD diagnosis relies almost exclusively on post-bronchodilator spirometry despite the heterogeneity of COPD. However, post-bronchodilator spirometry is neither sensitive for early pathological changes nor predictive of symptoms.2 As a result, COPD is often underdiagnosed or diagnosis is delayed, often until lung function is substantially impaired.2 Thus, making disease management more challenging. 
The Lancet commission put forth urgent recommendations for driving transformational change and assessing progress, acknowledging that evidence to support their proposals is currently lacking.2 
Dr Miravitlles concluded, “so far, the guidelines recommend a kind of treatment that is quite simplistic in the sense that despite the heterogeneity of the disease, we do not have evidence to recommend a more personalized therapy. Therefore, we are still treating the majority of patients in a quite a standardized way. As a result, some patients, particularly moderate to severe, are still experiencing exacerbations despite the therapy.”
<h3 class="Default" style="margin-top: 8px; margin-bottom: 6px;"><a>Panel discussion</a></h3>
Following Dr Miravitlles presentation, the panel of experts added their views on the current unmet needs in patients with COPD.
Dr Rogliani pointed out, “Post-bronchodilation spirometry is inadequate to detect early phase of the disease, which can really have an impact in terms of the natural history of the disease.” She further added that exacerbations are very different in terms of their nature, occurrence, and management approach.
Dr Han opined, “Not all COPD is related to tobacco smoke.” She added that patients may get COPD from occupational exposures, recurrent respiratory infections, asthma along with early life factors; therefore, exposure history is important from public health perspective. 
She emphasized upon, “Increasing public awareness, increasing physician awareness and trying to track and identify patients with a different idiotype and move them into clinical trials.” 
On this note, Dr Rogliani highlighted the need for a different approach towards COPD.
Dr Miravitlles agreed and highlighted, “We need to address different aspects of the disease, starting with the risk factors.” He also added that there is a need to pay attention to the most severe patients, who are on the so-called maximum therapy. 
Dr Han said that good therapies are available, but the primary need is for better therapies, because patients suffering from frequent exacerbations and significant morbidity and disability, despite the currently available therapies, still there.

The article "Current Unmet Needs for Patients with COPD" features insights from a round table discussion involving leading respiratory experts. It focuses on chronic obstructive pulmonary disease (COPD), a heterogeneous and progressive condition. The experts explore various aspects, such as the role of inflammatory pathways in disease progression, the importance of biomarkers in COPD management, and the significant global burden of COPD. The discussion also highlights the challenges in diagnosing COPD early, the impact of exacerbations on lung function and quality of life, and the need for more personalized treatment approaches .

Do blood eosinophils have a role in COPD?
In COPD, raised blood eosinophils (EOS) levels are associated with type 2 inflammation1 and have been linked to a higher risk of exacerbations.2 Understanding the role of EOS levels and their evolution through time can be important for clinicians to phenotype their patients and evaluate potential risk of exacerbation.3 However, a look-back period is warranted while assessing EOS levels in patients because EOS levels may fluctuate as a result of treatment.4
Discover more about the <a href="https://pro.campus.sanofi/copd/articles/role-of-type-2-inflammation" style="color:#0563c1; text-decoration:underline">Role of type 2 Inflammation in COPD</a>
Eosinophilic inflammation endotype 
Eosinophilic inflammation is a stable endotype. The <a href="https://bmjopen.bmj.com/content/4/3/e004546.long" style="color:#0563c1; text-decoration:underline">AERIS</a> study investigated the stability of this phenotype over time. The study results demonstrated that eosinophilic inflammation (blood EOS count ≥2%) is common at the time of exacerbation in patients with predominantly raised EOS during stable state.5 The likelihood of an exacerbation being eosinophilic was nine folds higher in patients with blood EOS ≥2% than in those with blood EOS &lt;2% at enrolment (OR = 9.16; 95% CI: 4.10–20.47­­­­­; P &lt;0.001).5
What is known about EOS level stability?
Temporal stability of EOS Levels 
The concept of temporal stability refers to the consistency of a biomarker over time.6 In a study by Landis et al., the blood EOS counts taken during stable COPD were reasonably reproducible.7 
A study by Long et al., provides robust data on the temporal stability of EOS levels in COPD patients. In their analysis of 225 patients from the COPDMAP cohort, Long and colleagues investigated EOS stability over 1 year using 2019 GOLD COPD thresholds (&lt;100, 100–&lt;300 and ≥300 EOS/μL).8 They found that 69.3% of patients had good stability of EOS levels from baseline to 1 year (measurements taken during stable state) within the same 2019 GOLD COPD thresholds.8 This temporal stability indicates that EOS levels measured during the stable phase of COPD are not random fluctuations but reflect an underlying and consistent inflammatory phenotype. Moreover, the study demonstrated that patients (no exacerbation, 66.7% patients; ≥1 exacerbation, 72.7% patients; ≥2 exacerbations, 74.3% patients) had stable blood EOS levels over 1 year when stratified into subgroups by number of exacerbations within a year.8 
Association between EOS levels and future exacerbation risk9,10

Yun et al., prospectively validated the association of increased EOS levels with exacerbations in COPD in the <a href="https://erj.ersjournals.com/content/31/4/869.long" style="color:#0563c1; text-decoration:underline">ECLIPSE</a> study.9 In this study, the researchers measured EOS levels during the stable phase and tracked the occurrence of exacerbations over a 3-year period.9 They found that raised EOS level (≥300 cells/μL) at baseline during the stable phase was a consistent predictor of risk of exacerbations in the following year (IRR = 1.20; 95% CI: 1.05–1.36 at 1 year).9 Specifically, the exacerbation risk was higher in patients with persistently raised (vs low) EOS levels, indicating that such patients had the greatest risk. Furthermore, the study revealed that the predictive capability of EOS levels extended beyond just a year (IRR = 1.22; 95% CI: 1.06–1.42 for overall study period).9 Patients with high EOS levels were consistently more likely to exacerbate over 3 years. This extended predictive capability underscores the utility of EOS level as a long-term predictor of exacerbation risk, allowing for early and proactive management strategies.9

Impact of oral corticosteroids use on blood EOS levels in patients with COPD
An inverse linear relationship between blood EOS levels and oral corticosteroids (OCS) dose was observed by Prazma et al., in patients with severe asthma, with an increase in blood EOS levels by 41% for every 5 mg/day decrease in OCS dose.11 To our knowledge, the impact of OCS use on blood EOS levels has not been studied in patients with COPD. However, OCS use is known to suppress EOS levels in patients with COPD.12 A study reported significant reduction in sputum EOS counts of six folds, following daily OCS use for 2 weeks.13 Measurement of EOS levels in patients whose levels are suppressed due to OCS administration could give an inaccurate assessment of EOS levels.12
Learn more about <a href="https://pro.campus.sanofi/copd/articles/blood-eosinophils-as-a-biomarker-in-patients-with-copd" style="color:#0563c1; text-decoration:underline">Blood Eosinophils as a Biomarker in Patients with COPD</a>
What are the clinical implications of EOS stability and predictive capability? 
The evidence supporting the EOS stability8 and long-term predictive capability9 of EOS levels in COPD has significant clinical implications. By identifying patients with consistently raised EOS levels, healthcare providers can stratify patients based on their risk of future exacerbations. This stratification can guide treatment decisions, particularly the use of OCS,14 inhaled (ICS)15 or biologics16 that target type 2 inflammation. For instance, a COPD patient with consistently high EOS levels (&gt;300 cells/μL) during the stable phase may be an ideal candidate for early intervention with ICS,15 which has been shown to reduce the frequency and severity of exacerbations in eosinophilic COPD.17,18 On the contrary, absence of raised blood EOS levels of &gt;2% may help identify a subgroup with an adverse impact of OCS on their recovery.14 The stability of EOS levels over time allows clinicians to monitor these levels as part of routine care, making it easier to identify changes in the patient’s inflammatory profile and adjust treatment accordingly. 
For further guidance on how to manage COPD patients please refer to the <a href="https://pro.campus.sanofi/copd/articles/gold-recommendations-for-treatment-and-management-of-copd" style="color:#0563c1; text-decoration:underline">GOLD Recommendations for Treatment and Management of COPD</a>

The long-term predictive capability of blood EOS levels9 is particularly useful, as it enables healthcare providers to anticipate and mitigate the risk of exacerbations, which are a major driver of morbidity and healthcare costs in COPD.14,19,20
How can EOS measurements be incorporated into clinical practice?
Incorporating EOS measurements into routine COPD management requires careful consideration of the data thresholds and the specific clinical context. The threshold of ≥300 cells/μL is commonly used to define raised EOS levels,9 based on evidence from multiple studies, including that by Yun et al.,9 However, some variability exists in the optimal threshold depending on the patient population and the specific outcomes being predicted.21
In practice, measuring EOS levels during the stable phase of COPD can be easily integrated into routine blood tests.22 Given the evidence of temporal stability, a single measurement can provide a reliable assessment of the patient’s eosinophilic phenotype.7 Patients with raised EOS levels should be closely monitored for signs of exacerbation,23 and consideration should be given to the early initiation of ICS1. Currently various clinical trials are in progress to evaluate the role of therapies targeting type 2 inflammation in COPD with raised EOS levels.24
Moreover, the predictive capability of EOS levels means that these measurements can inform long-term management strategies. For instance, patients with high baseline EOS levels may require more intensive follow-up and a lower threshold for escalating treatment in the event of early signs of exacerbation. This proactive approach can help reduce the frequency and severity of exacerbations, ultimately improving patient outcomes and reducing the burden on healthcare systems.22
Challenges and future directions
While the evidence supporting the use of EOS levels as a biomarker in COPD is compelling, several challenges remain. One challenge is the variability in EOS levels due to external factors such as infections,25 medications,21 and environmental exposures.26 These factors can influence EOS levels and potentially confound their predictive value. Therefore, it is essential for clinicians to interpret EOS measurements in the context of the patient’s overall clinical picture and consider repeat measurements if necessary.
Another challenge is the need for further research to refine the thresholds for EOS levels in different clinical scenarios. While the ≥300 cells/μL threshold is widely used, there is a need for more data to establish the optimal cut-off points for different patient populations and to validate these thresholds in diverse clinical settings.23
Future research should also explore the potential for combining EOS levels with other biomarkers and clinical features to enhance predictive accuracy. For example, integrating EOS measurements with markers of airway inflammation, such as fractional exhaled nitric oxide (FeNO),27,28 or with clinical features such as exacerbation history29, could provide a more comprehensive risk assessment tool for COPD patients.

This article highlights the stability and predictive value of blood eosinophil levels in COPD, showing their strong link to exacerbation risk. Consistently elevated eosinophil levels can guide personalized treatment, including early use of inhaled corticosteroids (ICS). Integrating eosinophil measurements into routine practice can improve long-term disease management and patient outcomes.

A review of the clinical implications of eosinophil stability and predictive capability in COPD

<h2 style="margin-bottom: 8px;">Recognizing Moderate Exacerbations: The Need for Vigilance</h2>
Moderate exacerbations are those that require treatment with short acting bronchodilators, systemic corticosteroids and/or antibiotics.2 Early recognition and prompt management of moderate exacerbations are critical to mitigating their impact on COPD progression and patient outcomes. 
Criteria for moderate exacerbation2,4

According to GOLD Group ABE assessment tool, patients with a history of 0 or 1 moderate exacerbation, not leading to hospitalization, but with significant symptom burden [CAT (COPD assessment test) ≥10 or a mMRC (modified Medical Research Council dyspnea questionnaire) ≥2] are categorized as GOLD Group B.2,5 Patients with ≥2 moderate exacerbations (or ≥1 exacerbation requiring hospitalization) are categorized as GOLD Group E, irrespective of symptom burden.2
For more information, please read <a href="https://pro.campus.sanofi/copd/articles/gold-recommendations-for-treatment-and-management-of-copd" style="color:blue; text-decoration:underline">GOLD recommendations for treatment and management of COPD</a>.
Clinicians must be vigilant for key indicators that may signal a need for hospitalization:
Potential indicators for hospitalization assessment*2

Recognizing these clinical signs and intervening promptly can help prevent moderate exacerbations from escalating to more severe levels; thereby, reducing the overall burden of COPD. Remote home monitoring of patients, including the use of patient-reported outcomes and spirometry,6 is essential to detecting exacerbations early and improving overall management.
Please click on the link to know <a href="https://pro.campus.sanofi/copd/articles/What-tests-can-help-diagnose-and-monitor-your-patients-with-COPD-" style="color:blue; text-decoration:underline">what tests can help diagnose and monitor your patients with COPD?</a>
<h2 style="margin-bottom: 8px;">Moderate Exacerbation: The Unseen Drivers of COPD Progression</h2>
Moderate and/or severe exacerbations are not merely transient events; they are pivotal in shaping the trajectory of COPD.5 Acute moderate exacerbations are linked with worsening of airflow obstruction and lung hyperinflation.7 Furthermore, patients with frequent moderate to severe exacerbations exhibit a more rapid decline in lung function — forced expiratory volume in 1 second of 40 mL/year and peak expiratory flow of 2.9 L/min/year — compared with those with infrequent exacerbations.8 
Dr Surya Bhatt, a distinguished professor of medicine at the University of Alabama at Birmingham and a COPD researcher talks about <a href="https://pro.campus.sanofi/copd/articles/the-burden-and-risk-of-exacerbations-in-copd-according-to-dr-surya-bhatt" style="color:blue; text-decoration:underline">the burden and risk of exacerbations in COPD</a>.

The likelihood of subsequent moderate and severe exacerbations, and death are increased by 1.58 times, 2.08 times and 1.85 times, respectively, for 3 years following one moderate exacerbation with high symptom burden compared with no exacerbation.5 The risk of future exacerbations increases with even one episode of moderate exacerbation; thus, each episode is critical.5
Risk of future exacerbations with increasing frequency of moderate exacerbations9

For healthcare providers (HCP), the ability to recognize and treat frequent exacerbations early is crucial. This requires a proactive approach to COPD management, including increased HCP awareness on treatment recommendations, patient education, the development of integrated care action plans, and the provision of timely access to appropriate therapies.10 Such strategies are essential to maintaining disease control, preventing exacerbations from escalating, and reducing the overall burden of COPD on both patients and the healthcare system.
Learn more about <a href="https://pro.campus.sanofi/copd/articles/understanding-and-managing-copd-exacerbations" style="color:blue; text-decoration:underline">understanding and managing COPD exacerbations</a>.
<h2 style="margin-bottom: 8px;">The Ripple Effect: Impact of Moderate Exacerbations on Quality of Life (QoL)</h2>
Frequent exacerbations significantly impact the QoL for patients with COPD.11,12 The psychological impact of exacerbations is also considerable. Studies have shown that patients with frequent exacerbations are more likely to suffer from anxiety, post-traumatic stress and depression,13 with reportedly high prevalence (depression: 19.4%–50.0%; anxiety 9.3%–58.0%) soon after recovery.14 This psychological burden not only affects QoL, but also complicates disease management by impairing treatment adherence and increasing the risk of future exacerbations.15
Read this article to learn more about <a href="https://pro.campus.sanofi/copd/articles/the-impact-of-exacerbations-in-copd" style="color:blue; text-decoration:underline">the impact of exacerbations in COPD</a>.
Economically, moderate exacerbations contribute to substantial healthcare costs. Data indicate that the direct costs associated with moderate exacerbation can range from $248 to $1,011 per episode, depending on the setting of care.16 Indirect costs, including lost productivity and the need for informal caregiving, further amplify the economic impact.17 Overall, exacerbations account for approximately 50%–75% of the total annual COPD-related healthcare costs, highlighting their significant economic burden.16
In conclusion, moderate exacerbations play a critical role in the clinical course of COPD, with significant implications for both patient outcomes and healthcare resources. By prioritizing the early recognition and management of these exacerbations, healthcare providers can help mitigate their impact on disease progression and improve the overall QoL for patients with COPD.18 This approach, supported by appropriate maintenance treatment and patient-centered care such as pulmonary rehabilitation, is essential to achieving optimal outcomes in COPD management.10

Exacerbations are key events in COPD1 that play a crucial role in disease progression. Although often managed in outpatient settings, exacerbations contribute significantly to the overall burden of COPD.2 These events are characterized by an acute worsening of respiratory symptoms, including increased dyspnea associated with cough and production of purulent sputum, increased wheezing and chest discomfort.1,3 These characteristics reflect an underlying inflammatory response2 that exacerbates the disease process.

Navigating the Hidden Burden: The Critical Role of Moderate Exacerbations in COPD

What if you could identify higher-risk patients?&nbsp;&nbsp;
A deeper look at the inflammation behind exacerbations could ignite new thinking in COPD. Look for blood eosinophils, a biomarker of COPD with Type 2 Inflammation, which may help you identify those patients at increased risk of exacerbations.
Watch the video below to better understand exacerbations in COPD and better identify patients at risk.&nbsp;&nbsp;&nbsp;

Understanding type 2 inflammation may help shed light on why some patients continue to exacerbate. Watch this video to learn how.

One minute to ignite new thinking in COPD

Ignite new thinking in COPD -&nbsp;COPD, chronic obstructive pulmonary disease
In patients with COPD, exacerbations may :&nbsp;
<ul>
 <li>Increase the risk of another&nbsp;1</li>
 <li>Accelerate lung function decline&nbsp;2</li>
 <li>Increase morbidity and mortality risk&nbsp;1,3-6</li>
</ul>
Different types of chronic inflammation have an important role in COPD&nbsp;7-15 
 Type 2 inflammation and beyond type 2 inflammation 
 Identifying COPD patients with type 2 inflammation may help determine those at increased risk of exacerbations 16 
 Look for blood eosinophils, a biomarker of COPD with type 2 inflammation 17,18, a, b 
 EOS ≥ 300 cells/ μL à 32% increased risk of COPD exacerbations 16a,b 
 Understanding type 2 inflammation in COPD may shed light on why some patients continue to experience exacerbations
a Results from an observational analysis of 1553 patients with GOLD spirometry grade 2-4 COPD evaluating the relationship between blood eosinophil count and COPD exacerbation risk. b Stratified analysis confirmed that increased exacerbation risk was driven by subjects with a history of frequent exacerbations, defined as ≥2 exacerbations per year.

Read video transcript

Understanding type 2 inflammation may help shed light on why some patients continue to exacerbate. Watch this video to learn how.

To read the full content, activate your Sanofi Campus account. Please confirm your email address in the email you received.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

This information will only be used to validate your account and will not be distributed.

title

Before starting exploring, we can suggest you specific and relevant content

Title

Create new password

To offer you a personalised experience, you must

Your profile is incomplete

The ADCT gives a measure of how controlled the eczema is. Answer these 6 simple questions with your patient to find the ADCT score. It will indicate proper course of action.

Atopic dermatitis, a type of eczema, may be affecting your Patient's life in more ways than you know.

Take the Atopic Dermatitis Control Test (ADCT)

Enjoy more exclusive content{newline}by <a>registering today</a>

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

This website is for US healthcare professionals only.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

We're usually a treasure chest of knowledge, but we couldn't find what you're looking for.

We were unable to find what you're searching for

Sanofi does not review or control the content of non-Sanofi websites. 
MAT-US-2405606-v1.0-06/2024

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for healthcare professionals and relevant for HCPs.  It contains information on Sanofi medicines, educational resources, and promotional contents.  By entering this site, you are confirming that you are a healthcare professional.  

MAT-US-2405606-v1.0-06/2024

Welcome to Sanofi Campus US

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My consents

{resultsCount, plural, one {result} other {results}}

Please log in to access to the results

You need to sign-in to your account in order to access medical content.

Please Log In

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

You are entering to Sanofi Content Site

You are about to leave the T1D website

Welcome to the T1D Step Ahead Sanofi website

Enjoy more exclusive content by registering today

One minute to ignite new thinking in COPD

Latest COPD articles

A video series on round table discussions featuring experts: Current unmet needs for patients with COPD

A review of the clinical implications of eosinophil stability and predictive capability in COPD

Navigating the Hidden Burden: The Critical Role of Moderate Exacerbations in COPD